These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 16018939)

  • 1. Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer.
    Salam MT; Ursin G; Skinner EC; Dessissa T; Reichardt JK
    Urol Oncol; 2005; 23(4):246-53. PubMed ID: 16018939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study.
    Hsing AW; Chen C; Chokkalingam AP; Gao YT; Dightman DA; Nguyen HT; Deng J; Cheng J; Sesterhenn IA; Mostofi FK; Stanczyk FZ; Reichardt JK
    Cancer Epidemiol Biomarkers Prev; 2001 Oct; 10(10):1077-82. PubMed ID: 11588134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of V89L SRD5A2 polymorphism with prostate cancer development in a Japanese population.
    Li Z; Habuchi T; Mitsumori K; Kamoto T; Kinoshitu H; Segawa T; Ogawa O; Kato T
    J Urol; 2003 Jun; 169(6):2378-81. PubMed ID: 12771801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The 5alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population.
    Giwercman YL; Abrahamsson PA; Giwercman A; Gadaleanu V; Ahlgren G
    Eur Urol; 2005 Oct; 48(4):679-85. PubMed ID: 16039774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphisms in the 5alpha reductase type 2 gene and urologic measures of BPH.
    Roberts RO; Bergstralh EJ; Farmer SA; Jacobson DJ; McGree ME; Hebbring SJ; Cunningham JM; Anderson SA; Thibodeau SN; Lieber MM; Jacobsen SJ
    Prostate; 2005 Mar; 62(4):380-7. PubMed ID: 15389785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Association of polymorphisms in testosterone 5-alpha-reductase II genotype and prognosis factors of prostate cancer].
    Tong M; Xu Z; Ai JK; Yuan YM; Yin Y; Wang JQ; Li HW; Liu JH; Xin DQ; Zhou LQ; Li M; Na YQ
    Zhonghua Wai Ke Za Zhi; 2004 Dec; 42(24):1493-6. PubMed ID: 15733480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association among polymorphisms in the steroid 5alpha-reductase type II (SRD5A2) gene, prostate cancer risk, and pathologic characteristics of prostate tumors in an Ecuadorian population.
    Paz-y-Miño C; Witte T; Robles P; Llumipanta W; Díaz M; Arévalo M
    Cancer Genet Cytogenet; 2009 Mar; 189(2):71-6. PubMed ID: 19215786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longer (TA)n repeat but not A49T and V89L polymorphisms in SRD5A2 gene may confer prostate cancer risk in South Indian men.
    Rajender S; Vijayalakshmi K; Pooja S; Madhavi S; Paul SF; Vettriselvi V; Shroff S; Singh L; Thangaraj K
    J Androl; 2009; 30(6):703-10. PubMed ID: 19443907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The SRD5A2 V89L polymorphism is associated with severity of disease in men with early onset prostate cancer.
    Scariano JK; Treat E; Alba F; Nelson H; Ness SA; Smith AY
    Prostate; 2008 Dec; 68(16):1798-805. PubMed ID: 18780294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. V89L polymorphism of the 5alpha-reductase Type II gene (SRD5A2), endogenous sex hormones, and prostate cancer risk.
    Boger-Megiddo I; Weiss NS; Barnett MJ; Goodman GE; Chen C
    Cancer Epidemiol Biomarkers Prev; 2008 Feb; 17(2):286-91. PubMed ID: 18268111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Codon 89 polymorphism in the human 5 alpha-reductase gene in primary breast cancer.
    Scorilas A; Bharaj B; Giai M; Diamandis EP
    Br J Cancer; 2001 Mar; 84(6):760-7. PubMed ID: 11259089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A missense substitution A49T in the steroid 5-alpha-reductase gene (SRD5A2) is not associated with prostate cancer in Finland.
    Mononen N; Ikonen T; Syrjäkoski K; Matikainen M; Schleutker J; Tammela TL; Koivisto PA; Kallioniemi OP
    Br J Cancer; 2001 May; 84(10):1344-7. PubMed ID: 11355945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors.
    Cussenot O; Azzouzi AR; Nicolaiew N; Mangin P; Cormier L; Fournier G; Valeri A; Cancel-Tassin G
    Eur Urol; 2007 Oct; 52(4):1082-7. PubMed ID: 17448593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germ-line genetic variation in the key androgen-regulating genes androgen receptor, cytochrome P450, and steroid-5-alpha-reductase type 2 is important for prostate cancer development.
    Lindström S; Wiklund F; Adami HO; Bälter KA; Adolfsson J; Grönberg H
    Cancer Res; 2006 Nov; 66(22):11077-83. PubMed ID: 17108148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in a Japanese population.
    Habuchi T; Suzuki T; Sasaki R; Wang L; Sato K; Satoh S; Akao T; Tsuchiya N; Shimoda N; Wada Y; Koizumi A; Chihara J; Ogawa O; Kato T
    Cancer Res; 2000 Jan; 60(2):305-8. PubMed ID: 10667581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of SRD5A2 sequence variants in susceptibility to hereditary and sporadic prostate cancer.
    Chang BL; Zheng SL; Isaacs SD; Turner AR; Bleecker ER; Walsh PC; Meyers DA; Isaacs WB; Xu J
    Prostate; 2003 Jun; 56(1):37-44. PubMed ID: 12746845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 Codon 72 and p21 codon 31 polymorphisms in prostate cancer.
    Huang SP; Wu WJ; Chang WS; Wu MT; Chen YY; Chen YJ; Yu CC; Wu TT; Lee YH; Huang JK; Huang CH
    Cancer Epidemiol Biomarkers Prev; 2004 Dec; 13(12):2217-24. PubMed ID: 15598783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Association between A49T polymorphism of SRD5A2 gene and risk of prostate cancer].
    Tong M; Ai JK; Yuan YM; Yin Y; Zhou LQ; Xin DQ; Li M; Na YQ
    Zhonghua Yi Xue Za Zhi; 2005 May; 85(19):1319-21. PubMed ID: 16029630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SRD5A2 V89L polymorphism and prostate cancer risk: a meta-analysis.
    Wang C; Tao W; Chen Q; Hu H; Wen XY; Han R
    Prostate; 2010 Feb; 70(2):170-8. PubMed ID: 19760631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Catechol-O-methyltransferase gene polymorphisms in benign prostatic hyperplasia and sporadic prostate cancer.
    Tanaka Y; Sasaki M; Shiina H; Tokizane T; Deguchi M; Hirata H; Hinoda Y; Okayama N; Suehiro Y; Urakami S; Kawakami T; Kaneuchi M; Pookot D; Igawa M; Okuyama A; Ishii N; Dahiya R
    Cancer Epidemiol Biomarkers Prev; 2006 Feb; 15(2):238-44. PubMed ID: 16492910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.